全文获取类型
收费全文 | 25220篇 |
免费 | 6267篇 |
国内免费 | 133篇 |
专业分类
耳鼻咽喉 | 724篇 |
儿科学 | 686篇 |
妇产科学 | 786篇 |
基础医学 | 922篇 |
口腔科学 | 2721篇 |
临床医学 | 4672篇 |
内科学 | 5728篇 |
皮肤病学 | 510篇 |
神经病学 | 2211篇 |
特种医学 | 1137篇 |
外科学 | 4446篇 |
综合类 | 97篇 |
现状与发展 | 12篇 |
一般理论 | 5篇 |
预防医学 | 3178篇 |
眼科学 | 447篇 |
药学 | 459篇 |
中国医学 | 27篇 |
肿瘤学 | 2852篇 |
出版年
2024年 | 136篇 |
2023年 | 1123篇 |
2022年 | 437篇 |
2021年 | 877篇 |
2020年 | 1305篇 |
2019年 | 655篇 |
2018年 | 1490篇 |
2017年 | 1410篇 |
2016年 | 1611篇 |
2015年 | 1687篇 |
2014年 | 2155篇 |
2013年 | 2584篇 |
2012年 | 1084篇 |
2011年 | 1029篇 |
2010年 | 1480篇 |
2009年 | 2064篇 |
2008年 | 914篇 |
2007年 | 667篇 |
2006年 | 815篇 |
2005年 | 583篇 |
2004年 | 459篇 |
2003年 | 408篇 |
2002年 | 376篇 |
2001年 | 435篇 |
2000年 | 328篇 |
1999年 | 423篇 |
1998年 | 523篇 |
1997年 | 502篇 |
1996年 | 552篇 |
1995年 | 407篇 |
1994年 | 318篇 |
1993年 | 273篇 |
1992年 | 215篇 |
1991年 | 194篇 |
1990年 | 186篇 |
1989年 | 201篇 |
1988年 | 162篇 |
1987年 | 169篇 |
1986年 | 141篇 |
1985年 | 133篇 |
1984年 | 107篇 |
1983年 | 120篇 |
1982年 | 103篇 |
1981年 | 86篇 |
1980年 | 70篇 |
1979年 | 54篇 |
1978年 | 55篇 |
1977年 | 66篇 |
1976年 | 49篇 |
1975年 | 58篇 |
排序方式: 共有10000条查询结果,搜索用时 375 毫秒
1.
2.
3.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
4.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
5.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献6.
7.
8.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
9.
10.